Clearmind Medicine Welcomes Inclusion of MEAI in New Legislation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5d ago
0mins
Should l Buy CMND?
Clearmind Medicine welcomes the inclusion of its proprietary compound, MEAI, in newly introduced bipartisan legislation in the U.S. Congress. The Expanding Veterans' Access to Emerging Treatments Act of 2026 directs the Department of Veterans Affairs to establish an investigational research and extended access treatment program for innovative and emerging therapies that address unmet medical needs in veterans. Covered therapies explicitly include psilocybin, MDMA, MEAI, 5-MeO-DMT, ibogaine, ketamine, and others as designated by the Secretary of Veterans Affairs. This marks the first time MEAI, Clearmind's proprietary, next-generation, non-hallucinogenic neuroplastogen, has been named in U.S. federal legislation. If passed, H.R. 7091 would transform clinical treatment across a variety of covered conditions, including Alcohol Use Disorder, by developing VA-supported clinical trials and extended access protocols using these emerging treatments. "We so greatly appreciate Congress introducing H.R. 7091, which offers a transformational opportunity for veterans suffering from alcoholism, post-traumatic stress disorder and other conditions to access emerging, promising therapies. We also appreciate the recognition of MEAI, a non-hallucinogenic neuroplastogen with the transformative potential to improve the health of veterans," said CEO Adi Zuloff-Shani. "We believe, this bipartisan milestone in Washington, D.C., underscores growing support for innovative, evidence-based approaches to conditions like post-traumatic stress disorder, which remains a significant challenge for many veterans."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CMND?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CMND
About CMND
Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio consists of 19 patent families including 31 granted patents.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cannabis Sector Update: Aurora's Strategic Shift Amid Record Medical Sales
- Aurora Financial Performance: Aurora Cannabis reported net revenue of $94.2 million for Q3 2026, a 7% year-over-year increase, with global medical cannabis sales reaching $76.2 million, accounting for over 80% of total sales, indicating strong growth potential in the high-margin medical market.
- Strategic Transformation Plan: Aurora announced plans to gradually exit select Canadian consumer cannabis markets to reduce sales and marketing costs, which is expected to significantly improve overall profit margins in the coming quarters.
- Canopy Growth Results: Canopy Growth reported net revenue of $90.4 million for Q3 2026, with a nearly 50% reduction in net loss despite weak international performance, reflecting positive progress in cost control and market integration.
- Cronos Brand Expansion: Cronos Group launched its premium Lord Jones brand in Israel, marking a significant step in its global expansion strategy aimed at meeting local market demands with high-quality products while enhancing brand recognition in international markets.
See More
Clearmind Regains Nasdaq Compliance with Share Price Above $1
- Compliance Restoration: Clearmind Medicine confirmed on December 30, 2025, that its common shares have maintained a closing price above $1 for the last 10 consecutive trading days, successfully regaining compliance with Nasdaq Listing Rule 5550(a)(2), indicating positive progress in stock price stability.
- Price Volatility Context: Previously, Clearmind was notified on December 4, 2025, of non-compliance due to its share price being below $1 for over 30 consecutive trading days, and this compliance restoration is expected to enhance investor confidence and attract more capital inflow.
- Market Reaction Expectations: With the restoration of compliance, Clearmind is likely to improve its market image and bolster investor confidence in its future growth potential, particularly in light of its commitment to developing novel psychedelic treatment solutions.
- Strategic Development Focus: Clearmind is currently focused on developing neuroplastic drugs targeting under-treated health issues and will continue to seek patent protection to enhance its intellectual property portfolio, further strengthening its competitiveness in the biotech sector.
See More
Clearmind Regains Nasdaq Compliance with Share Price Above $1
- Compliance Regained: Clearmind Medicine received confirmation from Nasdaq on December 30, 2025, that its share price exceeded $1 for the last 10 consecutive trading days, thereby regaining compliance with Nasdaq Listing Rule 5550(a)(2) and resolving previous compliance issues.
- Price Fluctuation Context: The company was notified on December 4, 2025, of non-compliance due to its common shares closing below $1 for over 30 consecutive trading days, highlighting market concerns regarding its stock price volatility.
- Future Growth Potential: Clearmind focuses on developing novel neuroplastogen-derived therapeutics, particularly for alcohol use disorder, which is expected to attract more investor interest in its innovative treatment solutions, further stabilizing and potentially increasing the company's stock price.
- Intellectual Property Strategy: The company currently holds 19 patent families and 31 granted patents, with plans to seek additional patents to enhance its market competitiveness, demonstrating a long-term strategic vision in the biotechnology sector.
See More
Clearmind Medicine Advances CMND-100 Clinical Trials for Alcohol Use Disorder
- Clinical Trial Progress: Clearmind successfully initiated its FDA-approved Phase I/IIa trial for CMND-100 at prestigious institutions like Yale and Johns Hopkins, achieving first-in-human dosing and demonstrating a favorable safety profile, marking a significant advancement in treating Alcohol Use Disorder.
- Safety Endorsement: The Data and Safety Monitoring Board unanimously approved the continuation of the clinical trial, reinforcing CMND-100's safety profile and laying a solid foundation for future data readouts, which boosts investor confidence.
- Global Footprint Expansion: Clearmind strengthened its intellectual property portfolio with multiple international patent filings targeting various indications, including weight loss and depression, showcasing the company's strategic positioning across multiple therapeutic areas.
- Future Outlook: Looking ahead to 2026, Clearmind aims to advance its pipeline, generate additional clinical data, and explore strategic opportunities to maximize shareholder value and patient impact, demonstrating its long-term commitment to the market.
See More
Clearmind Completes Patient Enrollment for Second Cohort of CMND-100 Trial
- Successful Patient Enrollment: Clearmind Medicine has successfully enrolled six patients for the second cohort in its FDA-approved Phase I/IIa trial of CMND-100, reflecting strong interest from clinical centers and potentially accelerating innovative treatment for AUD.
- Rapid Progress: The swift recruitment of the second cohort highlights the operational efficiency of collaborating with premier clinical sites like Johns Hopkins University, which may lead to faster clinical data generation and market opportunities for the company.
- Safety and Efficacy: The first cohort's trial results demonstrated a favorable safety profile and preliminary efficacy signals, indicating that CMND-100 could provide new solutions for treating AUD, addressing the needs of millions of patients worldwide.
- Future Outlook: With dosing for the second cohort expected to commence shortly, Clearmind anticipates topline results in the coming months, which will lay the groundwork for further development in the psychedelic pharmaceutical space.
See More
Clearmind Publishes Review on MEAI's Potential in Alcohol Use Disorder Treatment
- Therapeutic Potential Validation: Clearmind Medicine's published review confirms the potential of its candidate MEAI in treating alcohol use disorder, with studies indicating a significant reduction in drinking cravings within four hours, potentially addressing unmet treatment needs.
- Pharmacological Profile Analysis: MEAI's receptor interaction characteristics demonstrate its selectivity as a monoamine releaser, which may lead to lower abuse potential, providing a scientific basis for its application in psychedelic therapy.
- Safety Assessment: Although systematic studies on human volunteers are lacking, existing data suggest that MEAI has fewer adverse effects, with lower incidences of cardiovascular and psychological issues compared to MDMA, enhancing its appeal as a therapeutic agent.
- Intellectual Property Strategy: Clearmind holds 19 patent families and 31 granted patents, showcasing its research and development strength in the psychedelic space, and plans to pursue additional patents to expand its intellectual property portfolio.
See More
Cannabis Sector Update: Aurora's Strategic Shift Amid Record Medical Sales
- Aurora Financial Performance: Aurora Cannabis reported net revenue of $94.2 million for Q3 2026, a 7% year-over-year increase, with global medical cannabis sales reaching $76.2 million, accounting for over 80% of total sales, indicating strong growth potential in the high-margin medical market.
- Strategic Transformation Plan: Aurora announced plans to gradually exit select Canadian consumer cannabis markets to reduce sales and marketing costs, which is expected to significantly improve overall profit margins in the coming quarters.
- Canopy Growth Results: Canopy Growth reported net revenue of $90.4 million for Q3 2026, with a nearly 50% reduction in net loss despite weak international performance, reflecting positive progress in cost control and market integration.
- Cronos Brand Expansion: Cronos Group launched its premium Lord Jones brand in Israel, marking a significant step in its global expansion strategy aimed at meeting local market demands with high-quality products while enhancing brand recognition in international markets.
See More
Clearmind Regains Nasdaq Compliance with Share Price Above $1
- Compliance Restoration: Clearmind Medicine confirmed on December 30, 2025, that its common shares have maintained a closing price above $1 for the last 10 consecutive trading days, successfully regaining compliance with Nasdaq Listing Rule 5550(a)(2), indicating positive progress in stock price stability.
- Price Volatility Context: Previously, Clearmind was notified on December 4, 2025, of non-compliance due to its share price being below $1 for over 30 consecutive trading days, and this compliance restoration is expected to enhance investor confidence and attract more capital inflow.
- Market Reaction Expectations: With the restoration of compliance, Clearmind is likely to improve its market image and bolster investor confidence in its future growth potential, particularly in light of its commitment to developing novel psychedelic treatment solutions.
- Strategic Development Focus: Clearmind is currently focused on developing neuroplastic drugs targeting under-treated health issues and will continue to seek patent protection to enhance its intellectual property portfolio, further strengthening its competitiveness in the biotech sector.
See More
Clearmind Regains Nasdaq Compliance with Share Price Above $1
- Compliance Regained: Clearmind Medicine received confirmation from Nasdaq on December 30, 2025, that its share price exceeded $1 for the last 10 consecutive trading days, thereby regaining compliance with Nasdaq Listing Rule 5550(a)(2) and resolving previous compliance issues.
- Price Fluctuation Context: The company was notified on December 4, 2025, of non-compliance due to its common shares closing below $1 for over 30 consecutive trading days, highlighting market concerns regarding its stock price volatility.
- Future Growth Potential: Clearmind focuses on developing novel neuroplastogen-derived therapeutics, particularly for alcohol use disorder, which is expected to attract more investor interest in its innovative treatment solutions, further stabilizing and potentially increasing the company's stock price.
- Intellectual Property Strategy: The company currently holds 19 patent families and 31 granted patents, with plans to seek additional patents to enhance its market competitiveness, demonstrating a long-term strategic vision in the biotechnology sector.
See More
Clearmind Medicine Advances CMND-100 Clinical Trials for Alcohol Use Disorder
- Clinical Trial Progress: Clearmind successfully initiated its FDA-approved Phase I/IIa trial for CMND-100 at prestigious institutions like Yale and Johns Hopkins, achieving first-in-human dosing and demonstrating a favorable safety profile, marking a significant advancement in treating Alcohol Use Disorder.
- Safety Endorsement: The Data and Safety Monitoring Board unanimously approved the continuation of the clinical trial, reinforcing CMND-100's safety profile and laying a solid foundation for future data readouts, which boosts investor confidence.
- Global Footprint Expansion: Clearmind strengthened its intellectual property portfolio with multiple international patent filings targeting various indications, including weight loss and depression, showcasing the company's strategic positioning across multiple therapeutic areas.
- Future Outlook: Looking ahead to 2026, Clearmind aims to advance its pipeline, generate additional clinical data, and explore strategic opportunities to maximize shareholder value and patient impact, demonstrating its long-term commitment to the market.
See More
Clearmind Completes Patient Enrollment for Second Cohort of CMND-100 Trial
- Successful Patient Enrollment: Clearmind Medicine has successfully enrolled six patients for the second cohort in its FDA-approved Phase I/IIa trial of CMND-100, reflecting strong interest from clinical centers and potentially accelerating innovative treatment for AUD.
- Rapid Progress: The swift recruitment of the second cohort highlights the operational efficiency of collaborating with premier clinical sites like Johns Hopkins University, which may lead to faster clinical data generation and market opportunities for the company.
- Safety and Efficacy: The first cohort's trial results demonstrated a favorable safety profile and preliminary efficacy signals, indicating that CMND-100 could provide new solutions for treating AUD, addressing the needs of millions of patients worldwide.
- Future Outlook: With dosing for the second cohort expected to commence shortly, Clearmind anticipates topline results in the coming months, which will lay the groundwork for further development in the psychedelic pharmaceutical space.
See More
Clearmind Publishes Review on MEAI's Potential in Alcohol Use Disorder Treatment
- Therapeutic Potential Validation: Clearmind Medicine's published review confirms the potential of its candidate MEAI in treating alcohol use disorder, with studies indicating a significant reduction in drinking cravings within four hours, potentially addressing unmet treatment needs.
- Pharmacological Profile Analysis: MEAI's receptor interaction characteristics demonstrate its selectivity as a monoamine releaser, which may lead to lower abuse potential, providing a scientific basis for its application in psychedelic therapy.
- Safety Assessment: Although systematic studies on human volunteers are lacking, existing data suggest that MEAI has fewer adverse effects, with lower incidences of cardiovascular and psychological issues compared to MDMA, enhancing its appeal as a therapeutic agent.
- Intellectual Property Strategy: Clearmind holds 19 patent families and 31 granted patents, showcasing its research and development strength in the psychedelic space, and plans to pursue additional patents to expand its intellectual property portfolio.
See More
